Company intelligence / Profile preview

Shanghai Enkai Cell Technology

Shanghai, Shanghai, Chinapreqin.com ↗

Ownership: Private
Development stage: Other

Overview

Shanghai Enkai Cell Technology has advanced multiple proprietary NK cell-based therapies into early-stage clinical trials. Its lead program, NK042, is in Phase 1 for advanced solid tumors. Another program, NK010, has demonstrated promising anti-tumor activity and safety in preclinical studies and received FDA clearance for a clinical trial. The company leverages feeder-free large-scale expansion and high-efficiency gene modification technologies to create "off-the-shelf" allogeneic products targeting unmet needs in oncology and immune diseases.

Therapeutic areas: ImmunologyOncology
Modalities: NK cell therapyCAR-NK cell therapyImmune cell therapyFusion protein
Industry: Biotech

Drug pipeline

16 assets

NK010

15 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Shanghai Enkai Cell Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Enkai Cell Technology.

Explore the full profile